NuCana (NCNA) Hits New 12-Month Low at $9.56

Shares of NuCana PLC (NASDAQ:NCNA) hit a new 52-week low on Thursday . The stock traded as low as $9.56 and last traded at $10.41, with a volume of 56600 shares trading hands. The stock had previously closed at $10.37.

NCNA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of NuCana from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday. Cowen initiated coverage on shares of NuCana in a research report on Monday, October 23rd. They issued an “outperform” rating on the stock. William Blair initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an “outperform” rating for the company. Citigroup initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a “buy” rating and a $23.00 target price for the company. Finally, Jefferies Group initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $20.00.

The company has a market capitalization of $331.26 and a P/E ratio of -32.53.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sphera Funds Management LTD. acquired a new position in NuCana during the third quarter valued at approximately $919,000. Citadel Advisors LLC acquired a new position in shares of NuCana in the third quarter valued at approximately $1,218,000. Alyeska Investment Group L.P. acquired a new position in shares of NuCana in the third quarter valued at approximately $2,296,000. Perceptive Advisors LLC acquired a new position in shares of NuCana in the third quarter valued at approximately $3,674,000. Finally, Baillie Gifford & Co. acquired a new position in shares of NuCana in the third quarter valued at approximately $8,266,000. 22.27% of the stock is owned by institutional investors and hedge funds.

WARNING: “NuCana (NCNA) Hits New 12-Month Low at $9.56” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/12/28/nucana-ncna-hits-new-12-month-low-at-9-56-2.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit